JHVEPhoto / Shutterstock.com
Boston Scientific Corporation has announced the close of its acquisition of Axonics, Inc., a medical technology company focused on the development and commercialisation of differentiated devices to treat urinary and bowel dysfunction.
“Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence,” said Meghan Scanlon, Senior Vice President and President, Urology, Boston Scientific.
“By closing this acquisition, we’re pleased to welcome the Axonics team into Boston Scientific. The addition of the Axonics product portfolio enables us to expand into sacral neuromodulation, a high-growth adjacency for our Urology business, while bringing a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity.”
The purchase price of 71 USD cash per share represents an equity value of 3.7 billion USD and an enterprise value of 3.3 billion USD. The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive, due to amortisation expense and acquisition-related charges.
